Demant ASWILLF 90 EBITDA Margin % is 14.98% as of Dec. 2025, which is 30% below its 10-year median of 21.34. GuruFocus rates WILLF with a GF Score™ of 90/100 and a GF Value™ of $49.13 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Demant AS ranks better than 68.26% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Demant AS's EBITDA for the
six
months ended in Dec. 2025 was $275 Mil. Demant AS's Revenue for the
six
months ended in Dec. 2025 was $1,837 Mil. Therefore, Demant AS's EBITDA margin for the quarter that ended in Dec. 2025 was 14.98%.
Demant AS (OTCPK:WILLF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Demant AS EBITDA Margin % Related Terms
Demant AS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Demant AS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WILLF vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Demant AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Demant AS EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Demant AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Demant AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Demant AS (WILLF) has a EBITDA Margin % of 14.98% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Demant AS and its competitors. This is 30% below median its historical median of 21.34. Over the past decade, Demant AS's EBITDA Margin % has ranged from 15.91 to 25.89. According to the industry distribution chart, Demant AS ranks #259 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 31.7%.
Is Demant AS's EBITDA Margin % too high?
Demant AS's current EBITDA Margin % of 14.98% is 30% below median its 10-year median of 21.34. Over the past 10 years, this metric has ranged from a low of 15.91 to a high of 25.89. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Demant AS's value of 14.98% is 100.4% above this industry median. Based on the distribution chart, Demant AS ranks #259 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Demant AS has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Demant AS's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Demant AS ranks #259 out of 816 companies for EBITDA Margin %. This puts Demant AS in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Demant AS's value of 14.98% is 100.4% above this benchmark. Historically, Demant AS's own EBITDA Margin % has ranged from 15.91 to 25.89 over the past decade. While the company's 10-year median is 21.34 vs. the industry median of 7.48, Demant AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Demant AS's current EBITDA Margin % of 14.98% is 100.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Demant AS and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Demant AS's current EBITDA Margin % is 14.98%, which is 30% below median its own 10-year median of 21.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Demant AS stock overvalued right now?
Based on GuruFocus' analysis, Demant AS (WILLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $49.13, compared to a current price of $39.12 — trading 20.4% below its estimated fair value. The current EBITDA Margin % is 14.98%, which is 30% below median its 10-year median of 21.34 and 100.4% above the Medical Devices & Instruments industry median of 7.48. Demant AS's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Demant AS (WILLF), the current EBITDA Margin % is 14.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Demant AS (WILLF) Overvalued in 2026?
Based on GuruFocus' analysis, Demant AS stock appears to be undervalued.
The current stock price of $39.12 is trading 20.4% below its estimated GF Value™ of $49.13.
GuruFocus considers Demant AS to be Modestly Undervalued.
Key valuation signals for WILLF:
EBITDA Margin %: 14.98% (30% below median its 10-year median of 21.34)
GF Value™: $49.13 vs. price of $39.12 (20.4% below fair value)
Industry Position: 100.4% above the Medical Devices & Instruments median (#259 of 816)
No single metric tells the full story. See the WILLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Demant is a Denmark-based manufacturer and distributor of hearing solutions, such as hearing aid devices and diagnostic equipment. More than 80% of the company's sales come from North America and Europe.
90GF Score
Get the complete analysis for WILLF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WILLF has been successfully added to your 
